796967-16-3 Linifanib AKSci SYN1002
 
 
Loading Please Wait...
  SYN1002    
Linifanib, >95% (HPLC)
 
ABT-869
AL-39324
RG3635
IDENTITY
CAS Number:796967-16-3
MDL Number:MFCD11840918
MF:C21H18FN5O
MW:375.41
SPECIFICATIONS & PROPERTIES
Min. Purity Spec:>95% (HPLC)
Spectra:LCMS, HPLC
Physical Form (at 20°C):Off white to light brown powder
Long-Term Storage:Store long-term at -20°C
DOT/IATA TRANSPORT INFORMATION
Not hazardous material

BIOLOGICAL INFO
Solubility:DMSO 75mg/mL, Ethanol 5mg/mL
Application(s):PDGFR

REVIEW
 Linifanib (A 741439; A-741439; A741439; ABT-869; ABT869; RG3635) is an orally active multi-targeted receptor tyrosine kinase inhibitor for the treatment of various cancers. The compound is designed to inhibit vascular endothelial growth factor and platelet-derived growth factor receptors and is a multitargeted tyrosine kinase receptor inhibitor that suppresses FLT3 signaling. It is in phase III development for liver cancer and phase II development for non-small cell lung cancer, breast cancer, and colorectal cancer in the US, the EU and other areas of the world. (PMID:20698720); Recent research also indicates that Linifanib inhibits proliferation and induces apoptosis in AML patient cells via reduction of AKT and GSK3beta phosphorylation and maybe influential in AML therapy. (PMID:21471285)

GLOBALLY HARMONIZED SYSTEM (GHS)

Pictograms

Signal Word
Warning

Hazard Statements
H315; H319; H335

Precautionary Statements
P261; P264; P271; P280; P302+P352; P304+P340; P305+P351+P338; P312; P321; P332+P313; P337+P313; P362; P403+P233; P405; P501

Current as of December 8, 2021


Download SDS

For research use only. Not for diagnostic or therapeutic use. Not for human use. AK Scientific, Inc. does not sell to individuals. If you are a first-time customer, please email for review at least two official business documents issued by your local jurisdiction, state/province, or country.



PubChem